- Home
- SLS vs OLMA Comparison
SLS vs OLMA Comparison
Compare SLS & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLS | OLMA |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | 137 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 924.5M | 1.1B |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SLS | OLMA |
|---|---|---|
| Price | $12.00 | $12.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $10.00 | ★ $44.89 |
| AVG Volume (30 Days) | ★ 6.3M | 891.5K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | 15.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $110.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.39 | $4.47 |
| 52 Week High | $15.88 | $36.26 |
Technical Indicators
Market Signals| Indicator | SLS | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 52.09 | 51.82 |
| Support Level | $3.91 | $10.71 |
| Resistance Level | $15.88 | $12.81 |
| Average True Range (ATR) | 1.07 | 0.61 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 57.18 | 59.89 |
Price Performance
Historical ComparisonAbout SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.